What implications did the lack of inclusion of clean needles in the prevention package have for trial results?
For Researchers, not including clean needles in the prevention package was not right thing to do. And that shows that the consultations with stakeholders were not properly done. I am sure that somebody from stakeholders would have mentioned that clean needles was would be in prevention package. To avoid any misunderstanding and confusion about that study from stakeholders, Researchers need to know that consultations with different stakeholders from the community, should be done in beginning of protocol development to make sure that the trial will be conducted smoothly and the results will come out successfully. If the community is not involved from beginning, addressing issues that come later during the study, it is very difficult, that may affect not only bad trial results, but also credibility of researchers, and more energy. So later on they may have trouble to conduct other studies in future. It is time to all of us to think a head, and work together, increase collaboration, and consult each other in all stage of protocol development.
2) How can researchers engage stakeholders to better negotiate prevention packages that combine various arrays of options tailored to the needs of diverse subgroups?
First of all, researcher need to make a clear message to every stake holders. What I mean here, researcher team would select all stakeholders who will be involved in the study. Share with them the protocol and seek for inputs, sometimes researchers need to keep their protocol confidential, totally agree, that why we have to sign a confidential agreements, we would ask every one who will be selected to provide input to sign that. that is more reasonable that ending with troubles that may occur after, or getting bad results of the trial.
